Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ACRS Stock Forecast 2026-2027
$5.60
Current Price
$783.51M
Market Cap
Buy 10
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ACRS Price Targets
+185.7%
To High Target of $16.00
+78.6%
To Median Target of $10.00
-28.6%
To Low Target of $4.00
ACRS Price Momentum
-1.9%
1 Week Change
+29.0%
1 Month Change
+254.4%
1 Year Change
+86.0%
Year-to-Date Change
-4.3%
From 52W High of $5.85
+283.6%
From 52W Low of $1.46
📊 TOP ANALYST CALLS
Did ACRS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aclaris is one of their latest high-conviction picks.
Latest ACRS Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ACRS has a bullish consensus with a median price target of $10.00 (ranging from $4.00 to $16.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $5.60, the median forecast implies a 78.6% upside. This outlook is supported by 10 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ACRS Analyst Ratings
10
Buy
1
Hold
0
Sell
ACRS Price Target Range
Low
$4.00
Average
$10.00
High
$16.00
Current: $5.60
Latest ACRS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ACRS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2026 | LifeSci Capital | Outperform | Initiates | $13.00 | |
| May 5, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| May 5, 2026 | Guggenheim | Buy | Initiates | $N/A | |
| Apr 29, 2026 | Wedbush | Outperform | Maintains | $N/A | |
| Apr 16, 2026 | Oppenheimer | Outperform | Initiates | $N/A | |
| Mar 31, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Mar 19, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 28, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 21, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 20, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 10, 2025 | Piper Sandler | Biren Amin | Overweight | Assumes | $6.00 |
| Jun 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 28, 2025 | Wedbush | Outperform | Initiates | $N/A | |
| May 14, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| May 9, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| Mar 18, 2025 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Mar 7, 2025 | Scotiabank | Sector Outperform | Initiates | $N/A | |
| Dec 23, 2024 | HC Wainwright & Co. | Buy | Upgrade | $N/A | |
| Nov 19, 2024 | Leerink Partners | Outperform | Upgrade | $N/A | |
| Nov 19, 2024 | Jefferies | Buy | Upgrade | $N/A |
Aclaris Therapeutics Inc (ACRS) Competitors
The following stocks are similar to Aclaris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aclaris Therapeutics Inc (ACRS) Financial Data
Aclaris Therapeutics Inc has a market capitalization of $783.51M with a P/E ratio of -10.6x. The company generates $8.37M in trailing twelve-month revenue with a 6.9% profit margin.
Revenue growth is +37.2% quarter-over-quarter, while maintaining an operating margin of -1,111.8% and return on equity of -48.4%.
Valuation Metrics
Market Cap
$783.51M
Enterprise Value
$664.72M
P/E Ratio
-10.6x
PEG Ratio
-0.4x
Price/Sales
90.6x
Growth & Margins
Revenue Growth (YoY)
+37.2%
Gross Margin
+10.4%
Operating Margin
-1,111.8%
Net Margin
+6.9%
EPS Growth
+37.2%
Financial Health
Cash/Price Ratio
+13.5%
Current Ratio
4.0x
Debt/Equity
1.4x
ROE
-48.4%
ROA
-24.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aclaris Therapeutics Inc (ACRS) Business Model
About Aclaris Therapeutics Inc
What They Do
Develops novel drug candidates for immuno-inflammatory diseases.
Business Model
Aclaris Therapeutics operates through two segments: Therapeutics and Contract Research. The Therapeutics segment focuses on developing innovative therapies for conditions like atopic dermatitis and asthma, generating revenue primarily through the advancement of its drug candidates in clinical trials. The Contract Research segment provides laboratory services, adding another layer of income.
Additional Information
Founded in 2012 and based in Wayne, Pennsylvania, Aclaris is a clinical-stage biopharmaceutical company targeting unmet medical needs in immuno-inflammatory disorders. Its key product candidates include ATI-2138, ATI-052, and bosakitug, which are in various phases of clinical trials, showcasing the company's commitment to advancing treatments in immunology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
69
CEO
Dr. Neal S. Walker D.O., M.D.
Country
United States
IPO Year
2015
Website
www.aclaristx.comAclaris Therapeutics Inc (ACRS) Latest News & Analysis
Latest News
Quick Summary
Aclaris (ACRS) shares rose on high trading volume, but recent earnings estimate revisions indicate potential weakness ahead.
Why It Matters
Aclaris's share price surge on high volume indicates heightened investor interest, but negative earnings estimate revisions may signal potential future weakness.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Investing in penny stocks demands strong conviction, as many are considered "story stocks" with limited fundamentals.
Why It Matters
Penny stocks often lack solid fundamentals, relying on narratives. High risk and volatility can lead to substantial losses, impacting investment strategies and portfolio stability.
Source: MarketBeat
Market Sentiment:
Positive
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
1 month ago
Quick Summary
Aclaris Therapeutics (NASDAQ: ACRS) announced a busy clinical calendar, with upcoming readouts in its immunology pipeline and a planned Phase 2 asthma study for its lead bispecific antibody.
Why It Matters
Aclaris Therapeutics' busy clinical calendar and upcoming study highlights potential growth opportunities, affecting investor sentiment and stock performance in the biotech sector.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Aclaris Therapeutics (NASDAQ: ACRS) will participate in a fireside chat on June 4, 2026, at the Jefferies Global Healthcare Conference. A webcast will be available on their website.
Why It Matters
Aclaris' participation in the Jefferies Global Healthcare Conference signals potential insights into their pipeline and strategy, which could impact stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2 months ago
Quick Summary
Aclaris Therapeutics, Inc. (ACRS) presented at the Bank of America Global Healthcare Conference, discussing its developments and strategies.
Why It Matters
Aclaris Therapeutics' presentation at a major healthcare conference can influence investor sentiment and stock performance, highlighting potential growth and innovation in their pipeline.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Aclaris Therapeutics (NASDAQ: ACRS) will present at the Bank of America Healthcare Conference on May 14, 2026, at 9:35 AM PT. A webcast will be available on their website.
Why It Matters
Aclaris Therapeutics' presentation at a major healthcare conference could impact stock performance, providing insights into its pipeline and strategic direction, influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ACRS Stock
What is Aclaris Therapeutics Inc's (ACRS) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Aclaris Therapeutics Inc (ACRS) has a median price target of $10.00. The highest price target is $16.00 and the lowest is $4.00.
Is ACRS stock a good investment in 2027?
According to current analyst ratings, ACRS has 10 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ACRS stock?
Wall Street analysts predict ACRS stock could reach $10.00 in the next 12 months. This represents a 78.6% increase from the current price of $5.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aclaris Therapeutics Inc's business model?
Aclaris Therapeutics operates through two segments: Therapeutics and Contract Research. The Therapeutics segment focuses on developing innovative therapies for conditions like atopic dermatitis and asthma, generating revenue primarily through the advancement of its drug candidates in clinical trials. The Contract Research segment provides laboratory services, adding another layer of income.
What is the highest forecasted price for ACRS Aclaris Therapeutics Inc?
The highest price target for ACRS is $16.00 from at , which represents a 185.7% increase from the current price of $5.60.
What is the lowest forecasted price for ACRS Aclaris Therapeutics Inc?
The lowest price target for ACRS is $4.00 from at , which represents a -28.6% decrease from the current price of $5.60.
What is the overall ACRS consensus from analysts for Aclaris Therapeutics Inc?
The overall analyst consensus for ACRS is bullish. Out of 2 Wall Street analysts, 10 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ACRS stock price projections?
Stock price projections, including those for Aclaris Therapeutics Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 2:02 AM UTC